Av
Forskningsbolaget Bioinvent presenterar positiva resultat med läkemedelskandidaten BI-505 från en studie som genomförts av amerikanska forskare verksamma vid University of Utah i Salt Lake City, USA.
Läkemedelskandidaten BI-505 utvecklas för behandling av multipelt myelom, en cancersjukdom som urlakar skelettet. Preparatet är en human, monoklonal antikropp som binder till multipelt myelom-celler och får dem att begå självmord genom apoptos, programmerad celldöd. Prepararet har fått orphan drug-status av läkemedelsverken i både USA och Europa och testas idag i flera kliniska fas I-studier på olika center i USA och i Europa.
I den aktuella studien utvärderade de amerikanska forskarna effekten av BI-505 vid behandling av multipelt myeolom i studier på möss. Läkemedelskandidaten jämfördes dels med obehandlade djur och dels med djur som fått standardbehandling, kemoterapiläkemedlet Velcade. Effekten mättes genom att kontrollera nivån av humant IgG, en markör för multipelt myelom.
Forskarna tittade även specifikt på sjukdomens förmåga att bryta ned skelettet och fann att både BI-505 och Velcade hade positiv effekt på bentätheten hos djuren.
- Dagens läkemedelsbehandlingar av multipelt myelom är förknippade med svåra biverkningar. Vår förhoppning är att en antikroppsbaserad behandling kommer att uppvisa en förbättring i detta avseende. Med föreliggande preklinisk effektdata på BI-505, som mäter sig väl med ett av de ledande cellgifterna, har vi tagit ett steg i rätt riktning, säger Svein Mathisen, Bioinvents vd, i ett pressmeddelande.
Läkemedelskandidaten BI-505 utvecklas för behandling av multipelt myelom, en cancersjukdom som urlakar skelettet. Preparatet är en human, monoklonal antikropp som binder till multipelt myelom-celler och får dem att begå självmord genom apoptos, programmerad celldöd. Prepararet har fått orphan drug-status av läkemedelsverken i både USA och Europa och testas idag i flera kliniska fas I-studier på olika center i USA och i Europa.
I den aktuella studien utvärderade de amerikanska forskarna effekten av BI-505 vid behandling av multipelt myeolom i studier på möss. Läkemedelskandidaten jämfördes dels med obehandlade djur och dels med djur som fått standardbehandling, kemoterapiläkemedlet Velcade. Effekten mättes genom att kontrollera nivån av humant IgG, en markör för multipelt myelom.
Forskarna tittade även specifikt på sjukdomens förmåga att bryta ned skelettet och fann att både BI-505 och Velcade hade positiv effekt på bentätheten hos djuren.
- Dagens läkemedelsbehandlingar av multipelt myelom är förknippade med svåra biverkningar. Vår förhoppning är att en antikroppsbaserad behandling kommer att uppvisa en förbättring i detta avseende. Med föreliggande preklinisk effektdata på BI-505, som mäter sig väl med ett av de ledande cellgifterna, har vi tagit ett steg i rätt riktning, säger Svein Mathisen, Bioinvents vd, i ett pressmeddelande.
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"Mercodia has been a supplier of reliable assays since 1991" 
"We are entirely devoted to luminescence technology." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Novel products for CVD treatment and prevention." 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"We turn medical research into applications for better health and well-being." 
"We help our clients create significant business value through scientific expertise." 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
